Suppr超能文献

氢化可的松联合维生素C和硫胺素治疗脓毒症/脓毒性休克:一项系统评价及Meta分析和试验序贯分析

Hydrocortisone Combined with Vitamin C and Thiamine in the Treatment of Sepsis/Septic Shock: A Systematic Review with Meta-Analysis and Trial Sequential Analysis.

作者信息

Lu Difan, Mao Wenchao

机构信息

Cardiovascular Ultrasound Center of the First Affiliated Hospital, College of Medicine, Zhejiang University, Hangzhou, China.

Department of Critical Care Medicine, Zhejiang Hospital, Hangzhou, China.

出版信息

Clin Invest Med. 2023 Mar 26;46(1):E36-49. doi: 10.25011/cim.v46i1.40275.

Abstract

BACKGROUND

This study explored the efficacy of hydrocortisone combined with vitamin C and thiamine (HVT) in the treatment of sepsis/septic shock.

METHODS

PubMed, EMBASE and Web of Science were searched (establishment of the database to October 31, 2022). The meta-analysis included randomized controlled trials (RCTs); comparing the efficacy of HVT regimen and placebo in the treatment of sepsis/septic shock. The Cochrane Handbook for Systematic Reviews of Interventions was used to assess the risk of bias. The Review Manager 5.4 software was used for meta-analysis, and the relative risk (RR), mean difference (MD) and 95% confidence intervals (CI) were then determined. Trial sequential analysis (TSA) was then conducted.

RESULTS

Eight RCTs with 1,572 patients were identified. Meta-analysis showed that HVT regimen did not reduce all-cause (RR=0.96, 95% CI: 0.83 - 1.11, P=0.60), hospital (RR=1.03, 95% CI: 0.83 - 1.27, P=0.80) or intensive care unit (ICU) mortalities (RR=1.05, 95% CI: 0.86 - 1.28, P=0.65). Furthermore, there was no significant difference in the change of sequential organ failure assessment score, length of ICU stay, length of hospital stay, duration of the use of vasopressors, incidence of acute kidney injury and ventilator-free days between HVT and control groups. TSA showed that more trials are needed to confirm the results.

CONCLUSIONS

HVT regimen did not reduce the mortality of patients with sepsis/septic shock and was not associated with a significant improvement in outcomes. The TSA result showed that more RCTs with high quality and large sample sizes are needed to further confirm the results.

摘要

背景

本研究探讨氢化可的松联合维生素C和硫胺素(HVT)治疗脓毒症/脓毒性休克的疗效。

方法

检索了PubMed、EMBASE和Web of Science(数据库建立至2022年10月31日)。荟萃分析纳入随机对照试验(RCT);比较HVT方案与安慰剂治疗脓毒症/脓毒性休克的疗效。采用《Cochrane干预措施系统评价手册》评估偏倚风险。使用Review Manager 5.4软件进行荟萃分析,然后确定相对危险度(RR)、平均差(MD)和95%置信区间(CI)。随后进行试验序贯分析(TSA)。

结果

确定了8项RCT,共1572例患者。荟萃分析表明,HVT方案并未降低全因死亡率(RR = 0.96,95% CI:0.83 - 1.11,P = 0.60)、医院死亡率(RR = 1.03,95% CI:0.83 - 1.27,P = 0.80)或重症监护病房(ICU)死亡率(RR = 1.05,95% CI:0.86 - 1.28,P = 0.65)。此外,HVT组与对照组在序贯器官衰竭评估评分变化、ICU住院时间、住院时间、血管升压药使用持续时间、急性肾损伤发生率和无呼吸机天数方面无显著差异。TSA表明需要更多试验来证实结果。

结论

HVT方案未降低脓毒症/脓毒性休克患者的死亡率,且与结局的显著改善无关。TSA结果表明,需要更多高质量、大样本量的RCT来进一步证实结果。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验